sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY January 2014 | Archived Issues

Mark Your Calendar


Surgery Grand Rounds

Click the "read more" to see information about upcoming Surgery Grand Rounds.


Grand Rounds

Click here to view a schedule of all upcoming grand rounds.


Surgery Scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

Addition to Formulary Declined; PCEA Order Set Changed

Pharmacy Focus

The Pharmacy and Therapeutics Committee declined to add recombinant human thrombin to the formulary and took other actions at its Dec. 3 meeting. The committee also reduced the approved concentration of an epidural pain medication.

In addition, the U.S. Food and Drug Administration has issued warnings about methylphenidate products, some sodium phosphate medications and acetaminophen. The agency also added to the lists of contraindicated medications and drug interactions for Victrelis (boceprevir).

P and T Committee Approvals - Dec. 3 (PDF)  

PCEA Order Set Changed

Starting Jan. 22, the hydromorphone concentration in the hydromorphone/bupivacaine epidural will be reduced from 50mcg/ml to 25mcg/ml in the patient-controlled epidural analgesia (PCEA) CS-Link™ order set (1471). The Pharmacy and Therapeutics Committee approved the change.

FDA Warns of Priapism Risk With ADHD Medication

The U.S. Food and Drug Administration is warning that methylphenidate products, one type of stimulant drug used to treat attention deficit hyperactivity disorder (ADHD), may in rare instances cause prolonged and sometimes painful erections known as priapism.

Based on a recent review of methylphenidate products, the FDA updated drug labels and patient medication guides to include information about the rare but serious risk of priapism.

The FDA recommends that healthcare professionals talk to male patients and their caregivers to make sure they know the signs and symptoms of priapism and stress the need for immediate medical treatment should it occur. Younger males, especially those who have not yet reached puberty, may not recognize the problem or may be embarrassed to tell anyone if it occurs.

To learn more, visit this FDA Web page.

Constipation Drug Can Cause Harm if Taken More Than Once a Day

The FDA is warning of rare but serious harm from over-the-counter sodium phosphate medications used to treat constipation, if more than one dose is taken in 24 hours.

The agency has received reports of severe dehydration and changes in the levels of serum electrolytes from taking more than the recommended dose of OTC sodium phosphate products. The result can be serious adverse effects on organs, such as the kidneys and heart, and in some cases death.

These medications are available under the brand name Fleet and in generic formulations.

To learn more, visit this FDA Web page.

Limit Acetaminophen to 325 Milligrams per Unit, FDA says

The FDA is recommending that healthcare professionals stop prescribing and dispensing prescription combination drug products that contain more than 325 milligrams of acetaminophen per tablet, capsule or other dosage unit.

There are no available data to show that taking more than 325 mg of acetaminophen per dosage unit provides additional benefit that outweighs the added risks for liver injury, the agency said.

In the near future, the FDA said, it may withdraw approval for products containing more than 325 mg per dosage unit.

To learn more, visit this FDA Web page.

Contraindications, Interactions Updated for Victrelis

The FDA has approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and to update the drug interaction section.

Doxazosin, silodosin and tamsulosin, which are alpha 1-adrenoceptor antagonists, were added to the contraindications section due to the potential for alpha 1-adrenoceptor antagonist-associated adverse events such as hypotension and priapism.

In the drug interaction section, the calcium channel blockers amlodipine, diltiazem, nisoldipine and verapamil were added.